Rocket Pharmaceuticals is trading 7% down at $3.25 following the market close, despite a lack of fundamental news or corporate updates to explain the move.
- The stock closed the regular session at $3.50, and the current decline occurs in the absence of new earnings releases, FDA updates, or major corporate announcements.
- The price drop likely reflects thin after-hours liquidity and isolated selling rather than a fundamental shift in the company's valuation.
- With broader market indices showing only modest changes, the move appears disconnected from macroeconomic trends.